Eular 2022

Dit keer is het congres voor het eerst hybride: online en fysiek in Kopenhagen. Tijdens dit grootse internationale congres wisselen wetenschappers, artsen, behandelaars en patiënten de nieuwste inzichten en ontwikkelingen met elkaar uit over de bestrijding en behandeling van de diverse vormen van reuma. Reade is dit jaar weer goed vertegenwoordigd.

Met 11 posters en 8 presentaties laat Reade zien hoe de behandeling van reumatische aandoeningen verbeterd kan worden. Hieronder zie je welke kennis wij deze dagen delen.

Woensdag 1 juni

Sprekers:

• Wilfred Peter – What do you need to keep fit?
• Bas Dijkshoorn - Profound anticoagulant effects of initial antirheumatic treatments in early rheumatoid arthritis patients; a NORD-STAR spin-off study

Posters:

• Ronald van Vollenhoven - Impact of Upadacitinib Versus Abatacept on Individual Disease Outcomes in Patients With Rheumatoid Arthritis and Inadequate Responses to Biologic DMARDs
• Ronald van Vollenhoven - Sustained BICLA and BILAG Organ Domain Responses in Patients With Systemic Lupus Erythematosus (SLE) Receiving Anifrolumab in Two Phase 3 Trials
• Renske Hebing - Comparison of MTX-polyglutamate accumulation profiles in peripheral blood mononuclear cells and erythrocytes during 6 months MTX-therapy in the Methotrexate Monitoring (MeMo) trial
• Maureen Leeuw - Rheumatology patients treated with a bDMARD perspective towards therapeutic drug monitoring
• Sadaf Atiqi - Long-term Dynamics of antibody response to adalimumab detected with a drug tolerant assay
• Jim Wiegel - Screening with the Routine Assessment Of Patient Index Data 3 Questionnaire Can Reduce the Number Of Clinic Visits
• Reinder Raadsen - Cardiovascular disease risk in inflammatory arthritis still elevated in 2021!

Donderdag 2 juni

Sprekers:

• Laura Boekel - COVID-19 breakthrough infections in vaccinated patients with immune-mediated inflammatory diseases and controls – data from two prospective cohort studies

Vrijdag 3 juni

Sprekers:

• Maarten Boers - Favorable balance of benefit and harm of long-term, low dose prednisolone added to standard treatment in rheumatoid arthritis patients aged 65+: The pragmatic, multicenter, placebo- controlled GLORIA trial
• Maarten Boers - Multiple comparisons and the “nominal p”
• Ronald van Vollenhoven - Pragmatic Trials
• Ronald van Vollenhoven - Issues in recruitment (Covid and beyond)

Posters:

• Jim Wiegel - Adherence to telemonitoring disease activity by electronic patient reported outcomes in patients with inflammatory arthritis: a prospective cohort study
• Wendy Walrabenstein - Effect of a Multidisciplinary Lifestyle Program on Patients with Metabolic Syndrome-Associated Osteoarthritis: The Plants for Joints Randomized Controlled Trial
• Ronald van Vollenhoven - Efficacy of BIIB059 on skin manifestations in participants with systemic lupus erythematosus (SLE) in the Phase 2 LILAC Study (Part A)
• Bas Dijkshoorn - Coronary microvascular dysfunction in patients with rheumatoid arthritis and diabetes mellitus: a cross-sectional study with 13NH3 myocardial PET/CT

Zaterdag 4 juni

Sprekers:

• Ronald van Vollenhoven - nflammatory arthritis end-game: remission, lasting remission, and cure